CABAHealthcare · BiotechnologyThe 10 Wall Street analysts covering Cabaletta Bio, Inc. hold a median 12-month price target of $14 — +289.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 5 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cabaletta Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (82): The shares have been drifting up relative to others.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CABA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +289.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 14 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $4.00 → $3.00 |
| 15 May 2026 | Wells Fargo | Maintains | Equal-Weight | $2.00 → $4.00 |
| 15 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 May 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 24 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 24 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 31 Oct 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 10 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Sept 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 Aug 2025 | Citigroup | Maintains | Buy | — |
| 8 Aug 2025 | Guggenheim | Maintains | Buy | — |
| 8 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2025 | Citigroup | Maintains | Buy | — |
| 16 May 2025 | Guggenheim | Maintains | Buy | — |
| 15 May 2025 | Guggenheim | Maintains | Buy | — |
| 1 Apr 2025 | Guggenheim | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CABA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Cabaletta Bio, Inc. returned +125.3% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 36% of US stocks
Cheaper than 71% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cabaletta Bio, Inc. has a market value of $588.3M and an enterprise value of $388.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$181.3M.
Free cash flow in the twelve months to 30 June 2026: −$154.2M.
Trailing P/E: −1.6×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Cabaletta Bio, Inc. employs 154 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cabaletta Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cabaletta Bio announced plans to participate in the Wells Fargo 21st Annual Healthcare Conference, holding investor meetings on September 8, 2026, in Boston, MA.
Why it matters — CABA watchers would care because the company's scheduled investor meetings provide an opportunity for engagement with the financial community at a major healthcare conference.
Cabaletta Bio reported second quarter 2026 financial results and provided a business update. The company stated that registrational RESET-Myositis clinical data remain on track to be reported in mid-2027, supporting a planned BLA submission for rese-cel in the second half of 2027.
Why it matters — This update confirms that rese-cel, the company's key pipeline candidate, is on schedule for registrational data and a near-term regulatory filing, signaling steady progress toward a potential commercial launch.
The 10 Wall Street analysts covering Cabaletta Bio, Inc. have a median 12-month price target of $14, with estimates ranging from $3 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Cabaletta Bio, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cabaletta Bio, Inc. 31 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Cabaletta Bio, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +289.0% from the last close, and Ticker Nerd's factor model ranks Cabaletta Bio, Inc. 31 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cabaletta Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CABA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $30 over the next 12 months.
Cabaletta Bio, Inc. returned +125.3% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases.
The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Cabaletta Bio to Participate in Upcoming Investor Conferences". Cabaletta Bio announced plans to participate in the Wells Fargo 21st Annual Healthcare Conference, holding investor meetings on September 8, 2026, in Boston, MA.
Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s current programs center on targeted cell therapies designed to selectively eliminate disease-causing B cells while sparing healthy immune function. Its lead candidate, rese-cel, is being studied in the RESET clinical development program across autoimmune conditions including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta Bio also advances CAAR T cell approaches through its broader CABA platform, which is intended to address B cell–mediated autoimmune disorders. Based in Philadelphia, Cabaletta Bio plays a specialized role in the cell therapy market by focusing on precision immunology and disease-modifying treatments for patients with severe autoimmune disease.
CEO Dr. Steven A. Nichtberger M.D. · 154 employees · United States · https://www.cabalettabio.com
